Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com
Predictive Model Forecasts Advanced NSCLC Outcomes

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com
FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi
Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com
Legal Navigation Services Key to Addressing Disparities in Cancer Care

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com
Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
August 17th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 17th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

The Top 5 Most-Read Oncology Stories of 2020
December 28th 2020

The Top 5 Most-Read Oncology Stories of 2020

Rose McNulty
Our 5 most-read oncology stories and most-watched videos this year highlighted cancer care policy, diversity, and the growing practice of remote cancer care.
Mike Fazio, Archway Health
December 26th 2020

Mike Fazio on Choosing Between Oncology Care First or Another Oncology APM

Practices deciding whether to join Oncology Care First or another oncology alternative payment model (APM) will need a clear understanding of how big of a transformation they’ll need to make to their practice, said Mike Fazio.
Radiopharmaceuticals Are Showing Promise as the Next Generation of Cancer Treatment
December 24th 2020

Radiopharmaceuticals Are Showing Promise as the Next Generation of Cancer Treatment

JT Ripton
Recent major investments signal growth in an emerging therapeutic sector.
Community Oncology Alliance
December 21st 2020

COA Continues Effort to Stop Most Favored Nation Model

Rose McNulty
The Community Oncology Alliance's request includes declarations from community oncology practices detailing the anticipated ramifications should the Most Favored Nation rule become operative.
Kashyap Patel
December 15th 2020

Kashyap Patel, MD, Elected President of Community Oncology Alliance

Rose McNulty
Kashyap Patel, MD, associate editor of Evidence-Based Oncology, a publication of The American Journal of Managed Care, will serve a 1-year term beginning in January.
Basit Chaudhry, MD, PhD, Tuple Health
December 14th 2020

Dr Basit Chaudhry: How Practices Can Take Advantage of the Delay to Oncology Care First

With the start of Oncology Care First (OCF) being delayed, practices participating in the Oncology Care Model have more time to set themselves up to success when they transition to OCF, said Basit Chaudhry, MD, PhD, founder of Tuple Health.
Mike Fazio, Archway Health
December 9th 2020

Mike Fazio Discusses Data Lag Challenges in OCM and OCF

Throughout the Oncology Care Model (OCM), practices have dealt with a data lag, but in Oncology Care First (OCF) data is expected to be released more frequently, said Mike Fazio, of Archway Health.
Changes in Health Care
December 8th 2020

ASCO Releases Recommendations for Postpandemic Cancer Care

Rose McNulty
The American Society of Clinical Oncology calls on government bodies and the health care community to guide the cancer community’s post-pandemic recovery.
Adolescent and Young Adult Cancer
December 3rd 2020

AYA Cancer Rates Are Rising, New Study Finds

Rose McNulty
A new study published in JAMA Network Open found that the rate of cancer in adolescents and young adults increased by nearly 30% from 1973 to 2015.
Sara L. Douglas, PhD, RN, Frances Payne Bolton School of Nursing, Case Western Reserve University
December 3rd 2020

Dr Sara Douglas: Support Is Often Hard to Come By for Distance Caregivers

Distance caregivers of patients with cancer often find it difficult to enlist adequate support, noted Sara L. Douglas, PhD, RN, associate dean for research at the Frances Payne Bolton School of Nursing at Case Western Reserve University.
Randall Oyer, MD, president of the Association of Community Cancer Centers
November 24th 2020

Dr Randall Oyer on ACCC and ASCO's Work to Reduce Clinical Trial Disparities

Rose McNulty
Randall Oyer, MD, president of the Association of Community Cancer Centers, discusses the ACCC and American Society of Clinical Oncology's initiative to make clinical trials more inclusive.
Using Data to Drive Practice
November 20th 2020

How US Oncology Network Practices Find Success in the OCM

Rose McNulty
The Network enrolled its 100,000th patient in the Oncology Care Model (OCM) recently, and its practices are finding success in the complicated model.
Dr Karen Winkfield
November 17th 2020

Dr Karen Winkfield Discusses Importance of Workforce Diversity in Oncology

Representation of minority populations in the oncology workforce is important to educate physicians on the meaning of being culturally appropriate, and to provide culturally appropriate care.
Doctor Looking at Scan
November 12th 2020

Medicaid Expansion Associated With More Early-Stage Cancer Diagnoses

Rose McNulty
Data in a new analysis showed that Medicaid expansion under the Affordable Care Act had positive effects on rates of early-stage cancer diagnosis, and the results were immediate.
David Jackman, MD, Dana-Farber Cancer Institute
November 10th 2020

Dr David Jackman on Clinical Pathway Buy-in, Update Process

Efficiency, collaboration, and efficacy are key drivers in creating clinical pathway buy-in, with updates also vital to incorporate the latest trends and insights in cancer care.
Medicaid Expansion May Lower Mortality in Cancer Patients
November 5th 2020

Medicaid Expansion May Lower Mortality in Cancer Patients

Rose McNulty
Breast, lung, and colorectal cancer patients in Medicaid expansion states saw lower mortality rates compared with patients in nonexpansion states, a new study found.
How Federal Policy Decisions Are Influencing Cancer Care
November 2nd 2020

How Federal Policy Decisions Are Influencing Cancer Care

Laura Joszt, MA
As novel therapies drive up the cost of cancer care, federal policy decisions are being made that influence oncologists' ability to deliver cancer care, said Debra Patt, MD, PhD, MBA, MPH, of Texas Oncology.
Dr Kerin Adelson on Changes in Care Coordination Precipitated by OCM
November 1st 2020

Dr Kerin Adelson on Changes in Care Coordination Precipitated by OCM

Through the Oncology Care Model's impact on preventing unnecessary utilization, particularly for in-patient care, resources derived from its use has enhanced care coordination and led to the formation of novel infrastructure and clinical pathways.
Community Oncology Alliance
October 28th 2020

A Closer Look at 3 Oncology Payment Reform Projects

Mary Caffrey
Evolution and collaboration are the fundamentals of bringing oncology payment reform plans to fruition, say 3 professionals on the front lines.
Cancer Does Not Stop for COVID-19, But Reform Becomes a Challenge
October 28th 2020

Cancer Does Not Stop for COVID-19, but Reform Becomes a Challenge

Rose McNulty
During a session on day 1 of the Community Oncology Alliance (COA) Virtual Payer Exchange Summit on Oncology Payment Reform, a panel of experts discussed the ways COVID-19 continues to impact cancer care and payment reform.
Dr. Andre Goy
October 25th 2020

Dr Andre Goy Discusses Potential Benefits of Earlier Use of CAR T Therapies

Andre Goy, MD, chairman, director, and chief of the Division of Lymphoma at John Theurer Cancer Center in Hackensack, NJ, discussed the potential benefits of using CAR T-cell therapies as a second-line treatment.
Avalere Webinar on Oncology Care and Payment Reform
October 22nd 2020

Experts Discuss Oncology Care and Payment Reform in Avalere Webinar

Rose McNulty
Experts in cancer care and payment discussed the future of oncology care in a panel discussion hosted by Avalere Health on October 21, 2020.
Dr David Jackman on Dana Farber's Clinical Pathway Development Process
October 21st 2020

Dr David Jackman on Dana Farber's Clinical Pathway Development Process

At Dana Farber Cancer Institute, essential steps to developing clinical pathways include engaging physicians to buy-in, finding the optimal platform to store data, and displaying resulting content in a supportive and efficient way.
Lymphoma cell
October 16th 2020

Hodgkin Lymphoma Patients Face Noncancer Death Risk Despite Modern Therapies

Rose McNulty
A study and accompanying editorial from the Journal of Clinical Oncology found that Hodgkin lymphoma survivors still face a higher risk of non-cancer death than the general population.
Sara L. Douglas, PhD, RN, Case Western Reserve University
October 11th 2020

Dr Sara Douglas: Distance Caregivers of Patients With Cancer Have Distinct Needs

Distance caregivers have unique needs, explained Sara L. Douglas, PhD, RN, the Gertrude Perkins Oliva Professor in Oncology Nursing, associate dean for research, the Frances Payne Bolton School of Nursing, Case Western Reserve University.
Ibrance
October 10th 2020

Phase 2 Trial to Study Palbociclib in Early Stage Breast Cancer Based on ctDNA Monitoring

Rose McNulty
Natera’s Signatera ctDNA test will determine study eligibility and treatment effectiveness in HR-positive, HER2-negative breast cancer patients.
Dr Karen Winkfield on Improving Minority Access, Education for Precision Oncology
October 4th 2020

Dr Karen Winkfield on Improving Minority Access, Education for Precision Oncology

Addressing gaps in testing and education within precision oncology can assist in improving access to patients of color and other underserved populations.
Counties Experiencing Persistent Poverty Have Higher Cancer Mortality Rates
September 30th 2020

Counties Experiencing Persistent Poverty Have Higher Cancer Mortality Rates

Gianna Melillo
Throughout the United States, counties experiencing persistent poverty have disproportionately higher rates of cancer mortality, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.
Maura Abbott, PhD, AOCNP, CPNP, RN, Columbia University School of Nursing
September 29th 2020

Dr Maura Abbott Explains How Vaccine Form Determines Patient Contraindications

Form will determine in which patient populations, and why, a vaccine is not indicated for administration, said Maura Abbott, PhD, AOCNP, CPNP, RN, assistant professor of nursing at the Columbia University School of Nursing.
Addressing Cancer Disparities Requires Asking Questions and Putting Aside Assumptions
September 28th 2020

Addressing Cancer Disparities Requires Asking Questions and Putting Aside Assumptions

Laura Joszt, MA
Speakers at Patient-Centered Oncology Care® highlighted injustices in the US health care system, the risk of financial toxicity, and how providers can do a better job to ensure their patients achieve health equity, during a panel discussion.
<1
...
181920212223242526
...
187>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo